Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)

BACKGROUND: Candesartan cilexetil has been shown to effectively reduce blood pressure and cardiovascular risk. Whether it is advantageous to combine candesartan cilexetil with low-dose hydrochlorothiazide (HCTZ) or uptitrate it in cases of insufficient blood pressure control has not been fully inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Bönner, Gerd, Landers, Bernhard, Bramlage, Peter
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049544/
https://www.ncbi.nlm.nih.gov/pubmed/21415922
http://dx.doi.org/10.2147/VHRM.S17004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049544/
https://www.ncbi.nlm.nih.gov/pubmed/21415922
http://dx.doi.org/10.2147/VHRM.S17004

Ejemplares similares